Navigation Links
For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
Date:7/20/2009

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that most surveyed clinicians identify a need for additional therapies from the GLP-1 analogue and DPP-IV inhibitor drug classes for the treatment of type 2 diabetes. In particular, surveyed physicians identify a greater need for new GLP-1 analogues, owing to the shortcomings of the current GLP-1 analogue, Amylin/Eli Lilly's Byetta. Surveyed physicians indicate that Byetta's shortcomings include frequent injections and high levels of nausea associated with treatment. Additionally, clinicians indicate that the shortcomings of Merck's DPP-IV inhibitor Januvia include less glucose-lowering compared to metformin and a lack of long-term safety data.

The new Physician & Payer Forum report entitled A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? finds that 89 percent of surveyed endocrinologists and 77 percent of surveyed primary care physicians (PCPs) indicate there is a need for additional GLP-1 analogue therapies. The report also finds that 71 percent of endocrinologists and 74 percent of PCPs indicate there is a need for additional DPP-IV therapies.

Similarly, 75 percent of surveyed managed care organizations' (MCOs) pharmacy directors indicate that additional agents are needed within the GLP-1 analogue class, and 70 percent indicate a need for additional agents from the DPP-IV inhibitor class. Forty-five percent of MCOs indicate that a novel antidiabetic agent's glucose-lowering efficacy compared with that of existing drugs carries the most weight in their decision whether to include the novel drug in their formulary and to what tier it should be assigned.

"Surveyed clinicians indicate that although the feature of Januvia that they would most like to see improved in future DPP-IV inhibitors is its glucose-lowering efficacy, a lower cost than Januvia would be a more persuasive factor in their decision to prescribe a novel DPP-IV inhibitor," said Decision Resources Analyst Christine Helliwell, Ph.D. "Additionally, MCOs say the cost of a novel DPP-IV inhibitor relative to the cost of Januvia will strongly influence tier placement. As a result, cost could provide an effective differentiating feature for novel DPP-IV inhibitors."

A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? is based on a U.S. survey of 77 primary care physicians, 72 endocrinologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                    Decision Resources, Inc.
    Christopher Comfort                   Elizabeth Marshall
    781-296-2597                          781-296-2563
    ccomfort@dresources.com               emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
2. Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
3. Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India
4. Addiction Treatment Will Help Make Health Reform Affordable, New Analysis Shows
5. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
6. Cancer Patients Benefit From Speed, Accuracy of RapidArc Radiotherapy Treatments
7. Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments
8. New Outpatient Treatment for Heartburn-Related Problem Stops Esophageal Cancer Before It Starts
9. Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer
10. New Treatments for Alzheimers on the Horizon
11. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology: